<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GLIADEL- carmustine wafer </strong><br>Eisai Inc.<br></p></div>
<h1>
<span class="Bold">GLIADEL<span class="Sup">®</span> WAFER     Rx only</span><br>(polifeprosan 20 with carmustine implant)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">GLIADEL<span class="Sup">®</span> Wafer (polifeprosan 20 with carmustine implant) is a sterile, off-white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow wafer approximately 1.45 cm in diameter and 1 mm thick. Each wafer contains 192.3 mg of a biodegradable polyanhydride copolymer and 7.7 mg of carmustine [1,3-bis (2-chloroethyl)-1-nitrosourea, or BCNU]. Carmustine is a nitrosourea oncolytic agent. The copolymer, polifeprosan 20, consists of poly[bis(p-carboxyphenoxy) propane: sebacic acid] in a 20:80 molar ratio and is used to control the local delivery of carmustine. Carmustine is homogeneously distributed in the copolymer matrix.</p>
<p>The structural formula for polifeprosan 20 is:</p>
<div class="Figure"><img alt="
gliadel-01
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-01.jpg"></div>
<p>The structural formula for carmustine is:</p>
<div class="Figure"><img alt="
gliadel-02
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-02.jpg"></div>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First">GLIADEL<span class="Sup">®</span> Wafer is designed to deliver carmustine directly into the surgical cavity created when a <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> is resected. On exposure to the aqueous environment of the resection cavity, the anhydride bonds in the copolymer are hydrolyzed, releasing carmustine, carboxyphenoxypropane, and sebacic acid. The carmustine released from GLIADEL<span class="Sup">®</span> Wafer diffuses into the surrounding brain tissue and produces an antineoplastic effect by alkylating DNA and RNA.</p>
<p>Carmustine has been shown to degrade both spontaneously and metabolically. The production of an alkylating moiety, hypothesized to be chloroethyl carbonium ion, leads to the formation of DNA cross-links.</p>
<p>The tumoricidal activity of GLIADEL<span class="Sup">®</span> Wafer is dependent on release of carmustine to the tumor cavity in concentrations sufficient for effective cytotoxicity.</p>
<p>More than 70% of the copolymer degrades by three weeks. The metabolic disposition and excretion of the monomers differ. Carboxyphenoxypropane is eliminated by the kidney and sebacic acid, an endogenous fatty acid, is metabolized by the liver and expired as CO<span class="Sub">2</span> in animals.</p>
<p>The absorption, distribution, metabolism, and excretion of the copolymer in humans is unknown.  Carmustine concentrations delivered by GLIADEL<span class="Sup">®</span> Wafer in human brain tissue have not been determined. Plasma levels of carmustine after GLIADEL<span class="Sup">®</span> Wafer implant were not determined. In rabbits implanted with wafers containing 3.85% carmustine, no detectible levels of carmustine were found in the plasma or cerebrospinal fluid.</p>
<p>Following an intravenous infusion of carmustine at doses ranging from 30 to 170 mg/m<span class="Sup">2</span>, the average terminal half-life, clearance, and steady-state volume of distribution were 22 minutes, 56 mL/min/kg, and 3.25 L/kg, respectively. Approximately 60% of the intravenous 200 mg/m<span class="Sup">2</span> dose of <span class="Sup">14</span>C-carmustine was excreted in the urine over 96 hours and 6% was expired as CO<span class="Sub">2</span>.</p>
<p>GLIADEL<span class="Sup">®</span> Wafers are biodegradable in human brain when implanted into the cavity after tumor resection. The rate of biodegradation is variable from patient to patient. During the biodegradation process, a wafer remnant may be observed on brain imaging scans or at re-operation even though extensive degradation of all components has occurred. Data obtained from review of CT scans obtained 49 days after implantation of GLIADEL<span class="Sup">®</span> Wafer demonstrated that images consistent with wafers were visible to varying degrees in the scans of 11 of 18 patients. Data obtained at re-operation and autopsies have demonstrated wafer remnants up to 232 days after GLIADEL<span class="Sup">®</span> Wafer implantation.</p>
<p>Wafer remnants removed at re-operation from two patients with recurrent <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span>, one at 64 days and the second at 92 days after implantation, were analyzed for content. The following table presents the results of analyses completed on these remnants.</p>
<table width="80%">
<caption><span>
COMPOSITION OF WAFER REMNANTS REMOVED FROM TWO PATIENTS ON RE-OPERATION
</span></caption>
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Component
</th>
<th class="Botrule Lrule Rrule" align="center">
Patient A
</th>
<th class="Botrule Lrule Rrule" align="center">
Patient B
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">
Days After GLIADEL<span class="Sup">®</span> Wafer Implantation
</td>
<td class="Botrule Lrule Rrule" align="center">
64
</td>
<td class="Botrule Lrule Rrule" align="center">
92
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Anhydride Bonds
</td>
<td class="Botrule Lrule Rrule" align="center">
None detected
</td>
<td class="Botrule Lrule Rrule" align="center">
None detected
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Water Content (% of wafer remnant weight)
</td>
<td class="Botrule Lrule Rrule" align="center">
95-97%
</td>
<td class="Botrule Lrule Rrule" align="center">
74-86%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Carmustine Content (% of initial)
</td>
<td class="Botrule Lrule Rrule" align="center">
&lt;0.0004%
</td>
<td class="Botrule Lrule Rrule" align="center">
0.034%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
Carboxyphenoxypropane Content (% of initial)
</td>
<td class="Botrule Lrule Rrule" align="center">
9%
</td>
<td class="Botrule Lrule Rrule" align="center">
14%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
Sebacic Acid Content (% of initial)
</td>
<td class="Botrule Lrule Rrule" align="center">
4%
</td>
<td class="Botrule Lrule Rrule" align="center">
3%
</td>
</tr>
</tbody>
</table>
<p>The wafer remnants consisted mostly of water and monomeric components with minimal detectable carmustine present.
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionClinicalStudies"></a><a name="section-3"></a><p></p>
<h1>
CLINICAL STUDIES
</h1>
<p class="First"><span class="Bold Underline">Primary Surgery</span></p>
<p>A randomized, double-blind, placebo-controlled clinical trial was conducted in adult patients with newly-diagnosed high-grade <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> undergoing initial craniotomy for tumor resection. This trial determined the safety and efficacy of GLIADEL<span class="Sup">®</span> Wafer implants plus surgery and radiation therapy compared to placebo implants plus surgery and radiation therapy. Two hundred and forty patients with newly-diagnosed <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> were enrolled. The most common tumor type was <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma Multiforme</span> (GBM) (n=207), followed by anaplastic oligoastrocytoma (n=11), anaplastic <span class="product-label-link" type="condition" conceptid="40484128" conceptname="Oligodendroglioma">oligodendroglioma</span> (n=11), and <span class="product-label-link" type="condition" conceptid="4206182" conceptname="Astrocytoma, anaplastic">anaplastic astrocytoma</span> (n=2). GLIADEL<span class="Sup">®</span> Wafers were implanted at the time of the surgery in 120 patients and placebo wafers were implanted in 120 patients. The majority of patients received 6-8 wafers. The majority of patients (93/120, 77.5% in the GLIADEL<span class="Sup">®</span> Wafer group and 98/120, 81.7% in the placebo group) with newly-diagnosed <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> received a standard course of radiotherapy (55 to 60 Gy) typically starting 3 weeks after surgery. There were 17 patients (14.2%) in the GLIADEL<span class="Sup">®</span> Wafer group and 12 patients (10.0%) in the placebo group who received systemic chemotherapy during the study. All six patients with anaplastic <span class="product-label-link" type="condition" conceptid="40484128" conceptname="Oligodendroglioma">oligodendroglioma</span> received chemotherapy within 30 days of GLIADEL<span class="Sup">®</span> Wafer implantation. Patients were followed for at least three years or until <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Only one patient was lost to follow-up. Median survival increased from 11.6 months with placebo to 13.8 months with GLIADEL<span class="Sup">®</span> Wafer (p-value &lt;0.05, log-rank test). The hazard ratio for GLIADEL<span class="Sup">®</span> Wafer treatment was 0.73 (95% CI: 0.56-0.95).</p>
<p><span class="Bold">Kaplan-Meier Overall Survival Curves for Patients Undergoing Initial Surgery for a High-Grade <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">Malignant Glioma</span></span></p>
<div class="Figure"><img alt="
gliadel-03
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-03.jpg"></div>
<p>When only patients with <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">Glioblastoma multiforme</span> were included in the analysis, the hazard ratio with GLIADEL<span class="Sup">®</span> Wafer treatment was 0.78 (95% CI: 0.59-1.03, p=0.08, log-rank test).</p>
<p><span class="Bold Underline">Surgery for Recurrent Disease</span></p>
<p>A randomized, double-blind, placebo-controlled clinical trial was conducted in adult patients with recurrent <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span>. This trial determined the safety and efficacy of GLIADEL<span class="Sup">®</span> Wafer implants plus surgery compared to placebo implants plus surgery.</p>
<p>Ninety-five percent of the patients treated with GLIADEL<span class="Sup">®</span> Wafer had 7-8 wafers implanted. Chemotherapy was withheld at least four weeks (six weeks for nitrosoureas) prior to and two weeks after surgery in patients undergoing re-operation for <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span>. In 222 patients with recurrent <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> who had failed initial surgery and radiation therapy, the six-month survival rate after repeat surgery increased from 47% (53/112) for patients receiving placebo to 60% (66/110) for patients treated with GLIADEL<span class="Sup">®</span> Wafer. Median survival increased by 33%, from 24 weeks (5.5 months) with placebo to 32 weeks (7.4 months) with GLIADEL<span class="Sup">®</span> Wafer treatment. In patients with GBM, the six-month survival rate increased from 36% (26/73) with placebo to 56% (40/72) with GLIADEL<span class="Sup">®</span> Wafer treatment. Median survival of GBM patients increased by 41% from 20 weeks (4.6 months) with placebo to 28 weeks (6.4 months) with GLIADEL<span class="Sup">®</span> Wafer treatment. In patients with pathologic diagnoses other than GBM at the time of surgery for tumor recurrence, GLIADEL<span class="Sup">®</span> Wafer produced no survival prolongation.</p>
<p><span class="Bold">6-MONTH KAPLAN-MEIER SURVIVAL CURVES FOR PATIENTS UNDERGOING SURGERY FOR RECURRENT GBM</span></p>
<div class="Figure"><img alt="
gliadel-04
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-04.jpg"></div>
<p><span class="Bold">KAPLAN-MEIER OVERALL SURVIVAL CURVES FOR PATIENTS UNDERGOING SURGERY FOR RECURRENT GBM</span></p>
<div class="Figure"><img alt="
gliadel-05
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-05.jpg"></div>
<p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-4"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">GLIADEL<span class="Sup">®</span> Wafer is indicated in newly-diagnosed high-grade <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> patients as an adjunct to surgery and radiation. GLIADEL<span class="Sup">®</span> Wafer is indicated in recurrent <span class="product-label-link" type="condition" conceptid="40571980" conceptname="Glioblastoma multiforme">glioblastoma multiforme</span> patients as an adjunct to surgery.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-5"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First">GLIADEL<span class="Sup">®</span> Wafer contains carmustine. GLIADEL<span class="Sup">®</span> Wafer should not be given to individuals who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to carmustine or any of the components of GLIADEL<span class="Sup">®</span> Wafer.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-6"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First">Patients undergoing craniotomy for <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> and implantation of GLIADEL<span class="Sup">®</span> Wafer should be monitored closely for known complications of craniotomy, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, intracranial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, abnormal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, and <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">brain edema</span>. Cases of intracerebral <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> effect unresponsive to corticosteroids have been described in patients treated with GLIADEL<span class="Sup">®</span> Wafer, including one case leading to <span class="product-label-link" type="condition" conceptid="4273850" conceptname="Brain stem herniation">brain herniation</span>.</p>
<p><span class="Bold">Pregnancy:</span> There are no studies assessing the reproductive toxicity of GLIADEL<span class="Sup">®</span> Wafer. Carmustine, the active component of GLIADEL<span class="Sup">®</span> Wafer, can cause fetal harm when administered to a pregnant woman. Carmustine has been shown to be embryotoxic and teratogenic in rats at i.p. doses of 0.5, 1, 2, 4, or 8 mg/kg/day when given on gestation days 6 through 15. Carmustine caused <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (<span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, <span class="product-label-link" type="condition" conceptid="4140216" conceptname="Congenital micrognathism">micrognathia</span>, <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>) at 1.0 mg/kg/day (about 1/6 the recommended human dose (eight wafers of 7.7 mg carmustine/wafer) on a mg/m<span class="Sup">2</span> basis). Carmustine was embryotoxic in rabbits at i.v. doses of 4.0 mg/kg/day (about 1.2 times the recommended human dose on a mg/m<span class="Sup">2</span> basis). Embryotoxicity was characterized by increased embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>, reduced numbers of litters, and reduced litter sizes.</p>
<p>There are no studies of GLIADEL<span class="Sup">®</span> Wafer in pregnant women. If GLIADEL<span class="Sup">®</span> Wafer is used during pregnancy, or if the patient becomes pregnant after GLIADEL<span class="Sup">®</span> Wafer implantation, the patient must be warned of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-7"></a><p></p>
<h1>
PRECAUTIONS
</h1>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-8"></a><p></p>
<h1>
General
</h1>
<p class="First">Communication between the surgical resection cavity and the ventricular system should be avoided to prevent the wafers from migrating into the ventricular system and causing <span class="product-label-link" type="condition" conceptid="440385" conceptname="Obstructive hydrocephalus">obstructive hydrocephalus</span>. If a communication larger than the diameter of a wafer exists, it should be closed prior to wafer implantation.</p>
<p>Computed tomography and magnetic resonance imaging of the head may demonstrate enhancement in the brain tissue surrounding the resection cavity after implantation of GLIADEL<span class="Sup">®</span> Wafers. This enhancement may represent <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> caused by GLIADEL<span class="Sup">®</span> Wafer or <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-9"></a><p></p>
<h1>
Therapeutic Interactions
</h1>
<p class="First">Interactions of GLIADEL<span class="Sup">®</span> Wafer with other drugs have not been formally evaluated.</p>
<p>The short-term and long-term toxicity profiles of GLIADEL<span class="Sup">®</span> Wafer when given in conjunction with chemotherapy have not been fully explored. GLIADEL<span class="Sup">®</span> Wafer, when given in conjunction with radiotherapy does not appear to have any short-term or chronic toxicities.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-10"></a><p></p>
<h1>
Carcinogenesis, Mutagenesis, Impairment of Fertility
</h1>
<p class="First">No carcinogenicity, mutagenicity or impairment of fertility studies have been conducted with GLIADEL<span class="Sup">®</span> Wafer. Carcinogenicity, mutagenicity and impairment of fertility studies have been conducted with carmustine, the active component of GLIADEL<span class="Sup">®</span> Wafer. Carmustine was given three times a week for six months, followed by 12 months observation, to Swiss mice at i.p. doses of 2.5 and 5.0 mg/kg (about 1/5 and 1/3 the recommended human dose (eight wafers of 7.7 mg carmustine/wafer) on a mg/m<span class="Sup">2</span> basis) and to SD rats at i.p. dose of 1.5 mg/kg (about 1/4 the recommended human dose on a mg/m<span class="Sup">2</span> basis). There were increases in tumor incidence in all treated animals, predominantly subcutaneous and <span class="product-label-link" type="condition" conceptid="4128888" conceptname="Neoplasm of lung">lung neoplasms</span>. <span class="Italics">Mutagenesis</span>: Carmustine was mutagenic <span class="Italics">in vitro</span> (Ames assay, human lymphoblast HGPRT assay) and clastogenic both <span class="Italics">in vitro</span> (V79 hamster cell micronucleus assay) and <span class="Italics">in vivo</span> (SCE assay in rodent <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumors</span>, mouse bone marrow micronucleus assay). <span class="Italics">Impairment of Fertility</span>: Carmustine caused testicular degeneration at i.p. doses of 8 mg/kg/week for eight weeks (about 1.3 times the recommended human dose on a mg/m<span class="Sup">2</span> basis) in male rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-11"></a><p></p>
<h1>
Pregnancy
</h1>
<p class="First">Pregnancy Category D: see <span class="Underline"><a href="#splSectionWarnings">WARNINGS</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-12"></a><p></p>
<h1>
Nursing Mothers
</h1>
<p class="First">It is not known if either carmustine, carboxyphenoxypropane, or sebacic acid is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from carmustine in nursing infants, it is recommended that patients receiving GLIADEL<span class="Sup">®</span> Wafer discontinue nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-13"></a><p></p>
<h1>
Pediatric Use
</h1>
<p class="First">The safety and effectiveness of GLIADEL<span class="Sup">®</span> Wafer in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-14"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">Adverse reactions for the trials are described in the tables below.</p>
<p><span class="Bold Underline">Primary Surgery</span></p>
<p>The following data are the most frequently occurring adverse events observed in 5% or more of the newly-diagnosed <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> patients during the trial.</p>
<table width="80%">
<caption><span>
COMMON ADVERSE EVENTS OBSERVED IN ≥ 5% OF PATIENTS RECEIVING GLIADEL<span class="Sup">®</span> WAFER AT INITIAL SURGERY
</span></caption>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Body System<br>   Adverse Event
</th>
<th class="Botrule Lrule Rrule" align="center">
GLIADEL<span class="Sup">®</span> Wafer<br>[N=120]<br>n (%)
</th>
<th class="Botrule Lrule Rrule" align="center">
Placebo<br>[N=120]<br>n (%)
</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">
*Adverse events coded to the COSTART term "aggravation reaction" were usually events involving tumor/disease progression or general deterioration of condition (e.g. condition/health/Karnofsky/neurological/physical deterioration).
</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   Aggravation reaction*
</td>
<td class="Botrule Lrule Rrule" align="center">
98 (82)
</td>
<td class="Botrule Lrule Rrule" align="center">
95 (79)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
33 (28)
</td>
<td class="Botrule Lrule Rrule" align="center">
44 (37)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
26 (22)
</td>
<td class="Botrule Lrule Rrule" align="center">
18 (15)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
22 (18)
</td>
<td class="Botrule Lrule Rrule" align="center">
24 (20)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
21 (18)
</td>
<td class="Botrule Lrule Rrule" align="center">
21 (18)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
16 (13)
</td>
<td class="Botrule Lrule Rrule" align="center">
18 (15)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
2 (2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   Face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
3 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2 (2)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Cardiovascular system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep thrombophlebitis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (10)
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (9)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolus</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Digestive system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
26 (22)
</td>
<td class="Botrule Lrule Rrule" align="center">
20 (17)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
25 (21)
</td>
<td class="Botrule Lrule Rrule" align="center">
19 (16)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
23 (19)
</td>
<td class="Botrule Lrule Rrule" align="center">
14 (12)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function tests abnormal</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
1 (1)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Endocrine system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">Cushings syndrome</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (3)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Metabolic and nutritional disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4304198" conceptname="Impaired tissue repair">Healing abnormal</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
19 (16)
</td>
<td class="Botrule Lrule Rrule" align="center">
14 (12)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (9)
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (9)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Musculoskeletal system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Myasthenia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Nervous system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">Hemiplegia</span> 
</td>
<td class="Botrule Lrule Rrule" align="center">
49 (41)
</td>
<td class="Botrule Lrule Rrule" align="center">
53 (44)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
40 (33)
</td>
<td class="Botrule Lrule Rrule" align="center">
45 (38)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
28 (23)
</td>
<td class="Botrule Lrule Rrule" align="center">
25 (21)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Brain edema</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
27 (23)
</td>
<td class="Botrule Lrule Rrule" align="center">
23 (19)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Aphasia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
21 (18)
</td>
<td class="Botrule Lrule Rrule" align="center">
22 (18)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
19 (16)
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
13 (11)
</td>
<td class="Botrule Lrule Rrule" align="center">
18 (15)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   Speech disorder
</td>
<td class="Botrule Lrule Rrule" align="center">
13 (11)
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (9)
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial hypertension</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (9)
</td>
<td class="Botrule Lrule Rrule" align="center">
2 (2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality disorder</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">Facial paralysis</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking abnormal</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (9)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">Grand mal convulsion</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (3)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
5 (4)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3 (3)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
2 (2)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Respiratory system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (3)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Skin and appendages</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
14 (12)
</td>
<td class="Botrule Lrule Rrule" align="center">
13 (11)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (10)
</td>
<td class="Botrule Lrule Rrule" align="center">
14 (12)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Special senses</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">Conjunctival edema</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">Visual field defect</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorder</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
3 (3)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
1 (1)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Urogenital system</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
13 (11)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
</tr>
</tbody>
</table>
<p><span class="Bold Underline">Surgery for Recurrent Disease</span></p>
<p>The following post-operative adverse events were observed in 4% or more of the patients receiving GLIADEL<span class="Sup">®</span> Wafer at recurrent surgery. Except for nervous system effects, where there is a possibility that the placebo wafers could have been responsible, only events more common in the GLIADEL<span class="Sup">®</span> Wafer group are listed. These adverse events were either not present pre-operatively or worsened post-operatively during the follow-up period. The follow-up period was up to 71 months.
</p>
<table width="80%">
<caption><span>
COMMON ADVERSE EVENTS OBSERVED IN ≥ 4% OF PATIENTS RECEIVING GLIADEL<span class="Sup">®</span> WAFER AT SURGERY FOR RECURRENT DISEASE
</span></caption>
<col align="left" width="40%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">
Body System<br>Adverse Event
</th>
<th class="Botrule Lrule Rrule" align="center">
GLIADEL<span class="Sup">®</span> Wafer with Carmustine<br>[N=110]<br>n (%)
</th>
<th class="Botrule Lrule Rrule" align="center">
PLACEBO Wafer without Carmustine<br>[N=112]<br>n (%)
</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">
*p &lt; 0.05 for comparison of GLIADEL<span class="Sup">®</span> Wafer versus placebo groups
</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
13 (12)
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>*
</td>
<td class="Botrule Lrule Rrule" align="center">
8 (7)
</td>
<td class="Botrule Lrule Rrule" align="center">
1 (1)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Digestive System</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4304198" conceptname="Impaired tissue repair">Healing Abnormal</span>*
</td>
<td class="Botrule Lrule Rrule" align="center">
15 (14)
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
21 (19)
</td>
<td class="Botrule Lrule Rrule" align="center">
21 (19)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">Hemiplegia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
21 (19)
</td>
<td class="Botrule Lrule Rrule" align="center">
22 (20)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
16 (15)
</td>
<td class="Botrule Lrule Rrule" align="center">
14 (13)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
15 (14)
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (11)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
11 (10)
</td>
<td class="Botrule Lrule Rrule" align="center">
9 (8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Aphasia</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
10 (9)
</td>
<td class="Botrule Lrule Rrule" align="center">
12 (11)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Brain Edema</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (4)
</td>
<td class="Botrule Lrule Rrule" align="center">
1 (1)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Intracranial Hypertension</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (4)
</td>
<td class="Botrule Lrule Rrule" align="center">
7 (6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> or <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (4)
</td>
<td class="Botrule Lrule Rrule" align="center">
1 (1)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Skin and Appendages</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
4 (4)
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="3"><span class="Bold">Urogenital System</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
23 (21)
</td>
<td class="Botrule Lrule Rrule" align="center">
19 (17)
</td>
</tr>
</tbody>
</table>
<p>Post-marketing experience includes spontaneous reports of <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> formation after GLIADEL<span class="Sup">®</span> wafer implantation. These occurred at varying time intervals post-implantation. <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cyst</span> formation has also been reported in patients following resection of <span class="product-label-link" type="condition" conceptid="4253951" conceptname="Glioma, malignant, no ICD-O subtype">malignant glioma</span> who have not had Gliadel<span class="Sup">®</span> implanted.</p>
<p>The following four categories of adverse events are possibly related to treatment with GLIADEL<span class="Sup">®</span> Wafer. The frequency with which they occurred in the randomized trials along with descriptive detail is provided below.</p>
<p><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> In the initial surgery trial, the incidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was 33.3% in patients receiving GLIADEL<span class="Sup">®</span> Wafer and 37.5% in patients receiving placebo. <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">Grand mal seizures</span> occurred in 5% of GLIADEL<span class="Sup">®</span> Wafer-treated patients and 4.2% of placebo treated patients. The incidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> within the first 5 days after wafer implantation was 2.5% in the GLIADEL<span class="Sup">®</span> Wafer group and 4.2% in the placebo group. The time from surgery to the onset of the first post-operative <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> did not differ between the GLIADEL<span class="Sup">®</span> Wafer and placebo treated patients.</p>
<p>In the surgery for recurrent disease trial, the incidence of post-operative <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was 19% in both patients receiving GLIADEL<span class="Sup">®</span> Wafer and placebo. In this study, 12/22 (54%) of patients treated with GLIADEL<span class="Sup">®</span> Wafer and 2/22 (9%) of placebo patients experienced the first new or worsened <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> within the first five post-operative days. The median time to onset of the first new or worsened post-operative <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> was 3.5 days in patients treated with GLIADEL<span class="Sup">®</span> Wafer and 61 days in placebo patients.</p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">Brain Edema</span>:</span> In the initial surgery trial, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">brain edema</span> was noted in 22.5% of patients treated with GLIADEL<span class="Sup">®</span> Wafer and in 19.2% of patients treated with placebo. Development of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">brain edema</span> with <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> effect (due to tumor recurrence, intracranial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>) may necessitate re-operation and, in some cases, removal of GLIADEL<span class="Sup">®</span> Wafer or its remnants.</p>
<p><span class="Bold">3. Healing Abnormalities:</span> The following healing abnormalities have been reported in clinical trials of GLIADEL<span class="Sup">®</span> Wafer: <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span>, delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, subdural, subgaleal or <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusions</span>, and cerebrospinal fluid leak. In the initial surgery trial, healing abnormalities occurred in 15.8% of GLIADEL<span class="Sup">®</span> Wafer treated patients and in 11.7% of placebo recipients. Cerebrospinal fluid leaks occurred in 5% of GLIADEL<span class="Sup">®</span> Wafer recipients and 0.8% of those given placebo. During surgery, a water-tight dural closure should be obtained to minimize the risk of cerebrospinal fluid leak.</p>
<p>In the surgery for recurrent disease trial, the incidence of healing abnormalities was 14% in GLIADEL<span class="Sup">®</span> Wafer treated patients and 5% in patients receiving placebo wafers.</p>
<p><span class="Bold">4. Intracranial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> In the initial surgery trial, the incidence of <span class="product-label-link" type="condition" conceptid="435509" conceptname="Intracranial abscess">brain abscess</span> or <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> was 5% in patients treated with GLIADEL<span class="Sup">®</span> Wafer and 6% in patients receiving placebo. In the recurrent setting, the incidence of <span class="product-label-link" type="condition" conceptid="435509" conceptname="Intracranial abscess">brain abscess</span> or <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> was 4% in patients treated with GLIADEL<span class="Sup">®</span> Wafer and 1% in patients receiving placebo.</p>
<p>The following adverse events, not listed in the table above, were reported in less than 4% but at least 1% of patients treated with GLIADEL<span class="Sup">®</span> Wafer in all studies. The events listed were either not present pre-operatively or worsened post-operatively. Whether GLIADEL<span class="Sup">®</span> Wafer caused these events cannot be determined.</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (2%); <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span> (2%); <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span> (1%); <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (1%); <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (1%); <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (1%); <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (1%); <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (1%)</p>
<p><span class="Bold">Cardiovascular System:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (3%); <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (1%)</p>
<p><span class="Bold">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2%); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (2%); <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> (1%); <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (1%); <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span> (1%)</p>
<p><span class="Bold">Hemic and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (1%); <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> (1%)</p>
<p><span class="Bold">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (3%); <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (3%); <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (1%)</p>
<p><span class="Bold">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (1%)</p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span> (3%); <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (3%); <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> (2%); <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (2%); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2%); <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (2%); <span class="product-label-link" type="condition" conceptid="381548" conceptname="Monoplegia">monoplegia</span> (2%); <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> (1%); <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span> (1%); <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> (1%); <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span> (1%). In addition, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarct</span> were each reported in less than 1% of patients treated with GLIADEL<span class="Sup">®</span> Wafer.</p>
<p><span class="Bold">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (2%); <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span> (1%)</p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (2%)</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span> (2%); <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> (1%)</p>
<p><span class="Bold">Urogenital System:</span> <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> (2%)
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-15"></a><p></p>
<h1>
OVERDOSAGE
</h1>
<p class="First">There is no clinical experience with use of more than eight GLIADEL<span class="Sup">®</span> Wafers per surgical procedure.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-16"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Each GLIADEL<span class="Sup">®</span> Wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when eight wafers are implanted. It is recommended that eight wafers be placed in the resection cavity if the size and shape of it allows. Should the size and shape not accommodate eight wafers, the maximum number of wafers as allowed should be placed. Since there is no clinical experience, no more than eight wafers should be used per surgical procedure.</p>
<p><span class="Bold">Handling and Disposal</span><span class="Sup">1-7</span><span class="Bold">:</span> Wafers should only be handled by personnel wearing surgical gloves because exposure to carmustine can cause severe burning and hyperpigmentation of the skin. Use of double gloves is recommended and the outer gloves should be discarded into a biohazard waste container after use. A surgical instrument dedicated to the handling of the wafers should be used for wafer implantation. If repeat neurosurgical intervention is indicated, any wafer or wafer remnant should be handled as a potentially cytotoxic agent.</p>
<p>GLIADEL<span class="Sup">®</span> Wafer should be handled with care. The aluminum foil laminate pouches containing GLIADEL<span class="Sup">®</span> Wafer should be delivered to the operating room and remain unopened until ready to implant the wafers. <span class="Bold">The outside surface of the outer foil pouch is not sterile.</span></p>
<p><span class="Bold">Instructions for Opening Pouch Containing GLIADEL<span class="Sup">®</span> Wafer</span></p>
<p><span class="Bold">Figure 1:</span> To remove the sterile inner pouch from the outer pouch, locate the folded corner and slowly pull in an outward motion.</p>
<div class="Figure"><img alt="
gliadel-06
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-06.jpg"></div>
<p><span class="Bold">Figure 2:</span> Do NOT pull in a downward motion rolling knuckles over the pouch. This may exert pressure on the wafer and cause it to break.</p>
<div class="Figure"><img alt="
gliadel-07
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-07.jpg"></div>
<p><span class="Bold">Figure 3:</span> Remove the inner pouch by grabbing hold of the <span class="Bold">crimped</span> edge and pulling upward.</p>
<div class="Figure"><img alt="
gliadel-08
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-08.jpg"></div>
<p><span class="Bold">Figure 4:</span> To open the inner pouch, gently hold the crimped edge and cut in an arc-like fashion around the wafer.</p>
<div class="Figure"><img alt="
gliadel-09
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-09.jpg"></div>
<p><span class="Bold">Figure 5:</span> To remove the GLIADEL<span class="Sup">®</span> Wafer, gently grasp the wafer with the aid of forceps and place it onto a designated sterile field.</p>
<div class="Figure"><img alt="
gliadel-10
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-10.jpg"></div>
<p>Once the tumor is resected, tumor pathology is confirmed, and hemostasis is obtained, up to eight GLIADEL<span class="Sup">®</span> Wafers (polifeprosan 20 with carmustine implant) may be placed to cover as much of the resection cavity as possible. Slight overlapping of the wafers is acceptable. Wafers broken in half may be used, but wafers broken in more than two pieces should be discarded in a biohazard container. Oxidized regenerated cellulose (Surgicel<span class="Sup">®</span>) may be placed over the wafers to secure them against the cavity surface. After placement of the wafers, the resection cavity should be irrigated and the dura closed in a water tight fashion.</p>
<p>Unopened foil pouches may be kept at ambient room temperature for a maximum of six hours at a time.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-17"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">GLIADEL<span class="Sup">®</span> Wafer is available in a single dose treatment box containing eight individually pouched wafers. Each wafer contains 7.7 mg of carmustine and is packaged in two aluminum foil laminate pouches. The inner pouch is sterile and is designed to maintain product <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> and protect the product from moisture. The outer pouch is a peelable overwrap. <span class="Bold">The outside surface of the outer pouch is not sterile.</span></p>
<p>GLIADEL<span class="Sup">®</span> Wafer must be stored at or below -20°C (-4°F).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="splSectionReferences"></a><a name="section-18"></a><p></p>
<h1>
REFERENCES
</h1>
<ol class="Arabic">
<li>Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs, NIH Publication No. 83-2621. For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402.</li>
<li>AMA Council Report, Guidelines for Handling Parenteral Antineoplastics. JAMA, 1985; 253(11):1590-1592.</li>
<li>National Study Commission on Cytotoxic Exposure -- Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.</li>
<li>Clinical Oncological Society of Australia, Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia, 1983; 1:426-428.</li>
<li>Jones RB, et al: Safe Handling of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. CA -- A Cancer Journal for Clinicians, 1983; (Sept/Oct) 258-263.</li>
<li>American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J. Hosp Pharm, 1990; 47:1033-1049.</li>
<li>OSHA Work-Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs. Am J Hosp Pharm, 1986; 43:1193-1204.</li>
</ol>
<p class="First">NDC: 62856-177-08</p>
<p><span class="Bold">CAUTION:</span> FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION.</p>
<p>Manufactured by</p>
<p>Eisai Inc.<br>Woodcliff Lake, NJ 07677</p>
<p>Rev. 04/2010</p>
<p>201241</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-19"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">NDC 62856-177-08</p>
<p>Caution Card:</p>
<div class="Figure"><img alt="
gliadel-11
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-11.jpg"></div>
<p>Pouch Label:</p>
<div class="Figure"><img alt="
gliadel-12
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-12.jpg"></div>
<p>Box Label:</p>
<div class="Figure"><img alt="
gliadel-13
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=783ec80b-95d7-44c7-8b90-fa7394f50f67&amp;name=gliadel-13.jpg"></div>
<p>  </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GLIADEL 		
					</strong><br><span class="contentTableReg">polifeprosan 20 with carmustine implant wafer</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62856-177</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRACAVITARY</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARMUSTINE</strong> (CARMUSTINE) </td>
<td class="formItem">CARMUSTINE</td>
<td class="formItem">7.7 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLIFEPROSAN 20</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62856-177-08</td>
<td class="formItem">8  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020637</td>
<td class="formItem">09/24/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Eisai Inc.
							(831600833)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Eisai Inc. (831600833)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Eisai Inc.</td>
<td class="formItem"></td>
<td class="formItem">624009093</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>783ec80b-95d7-44c7-8b90-fa7394f50f67</div>
<div>Set id: 783ec80b-95d7-44c7-8b90-fa7394f50f67</div>
<div>Version: 1</div>
<div>Effective Time: 20100507</div>
</div>
</div> <div class="DistributorName">Eisai Inc.</div></p>
</body></html>
